Literature DB >> 34871363

CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.

Marion Alcantara1,2, Caroline Houillier3, Marie Blonski4, Marie-Thérèse Rubio5,6, Lise Willems7, Agathe Waultier Rascalou8, Magali Le Garff-Tavernier9, Karim Maloum9, Clotilde Bravetti9, Laetitia Souchet10, Damien Roos-Weil10, Véronique Morel10, Madalina Uzunov10, Carole Metz11, Meriem Dhib-Charfi11, Stéphanie Nguyen10, Natalia Shor12, Dimitri Psimaras3, Nicolas Weiss13, Nathalie Jacque10, Silvia Solorzano10, Nicolas Gauthier10, Marie Le Cann10, Françoise Norol10, Carole Soussain1,2, Sylvain Choquet10.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 34871363      PMCID: PMC8814680          DOI: 10.1182/blood.2021012932

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  20 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

3.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

4.  Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.

Authors:  Xiuli Wang; Miriam Walter; Ryan Urak; Lihong Weng; Christian Huynh; Laura Lim; ChingLam W Wong; Wen-Chung Chang; Sandra H Thomas; James F Sanchez; Lu Yang; Christine E Brown; Flavia Pichiorri; Myo Htut; Amrita Y Krishnan; Stephen J Forman
Journal:  Clin Cancer Res       Date:  2017-10-23       Impact factor: 12.531

5.  Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.

Authors:  Kevin R Parker; Denis Migliorini; Eric Perkey; Kathryn E Yost; Aparna Bhaduri; Puneet Bagga; Mohammad Haris; Neil E Wilson; Fang Liu; Khatuna Gabunia; John Scholler; Thomas J Montine; Vijay G Bhoj; Ravinder Reddy; Suyash Mohan; Ivan Maillard; Arnold R Kriegstein; Carl H June; Howard Y Chang; Avery D Posey; Ansuman T Satpathy
Journal:  Cell       Date:  2020-09-21       Impact factor: 41.582

6.  Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.

Authors:  S Kuramitsu; M Ohno; F Ohka; S Shiina; A Yamamichi; A Kato; K Tanahashi; K Motomura; G Kondo; M Kurimoto; T Senga; T Wakabayashi; A Natsume
Journal:  Cancer Gene Ther       Date:  2015-10-09       Impact factor: 5.987

Review 7.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

8.  Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.

Authors:  Matthew J Frigault; Jorg Dietrich; Maria Martinez-Lage; Mark Leick; Bryan D Choi; Zachariah DeFilipp; Yi-Bin Chen; Jeremy Abramson; Jennifer Crombie; Philippe Armand; Lakshmi Nayak; Chris Panzini; Lauren S Riley; Kathleen Gallagher; Marcela V Maus
Journal:  Blood       Date:  2019-07-18       Impact factor: 25.476

View more
  4 in total

1.  Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.

Authors:  Matthew J Frigault; Jorg Dietrich; Kathleen Gallagher; Mark Roschewski; Justin T Jordan; Deborah Forst; Scott R Plotkin; Daniella Cook; Keagan S Casey; Kevin A Lindell; Gabriel D Depinho; Katelin Katsis; Eva Lynn Elder; Mark B Leick; Bryan Choi; Nora Horick; Frederic Preffer; Meredith Saylor; Steven McAfee; Paul V O'Donnell; Thomas R Spitzer; Bimalangshu Dey; Zachariah DeFilipp; Areej El-Jawahri; Tracy T Batchelor; Marcela V Maus; Yi-Bin Chen
Journal:  Blood       Date:  2022-04-14       Impact factor: 25.476

Review 2.  Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.

Authors:  Yujia Zhai; Xiangxiang Zhou; Xin Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-04       Impact factor: 5.485

3.  Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.

Authors:  Huanxin Zhang; Zhiling Yan; Ying Wang; Yuekun Qi; Yongxian Hu; Ping Li; Jiang Cao; Meng Zhang; Xia Xiao; Ming Shi; Jieyun Xia; Sha Ma; Jianlin Qiao; Hujun Li; Bin Pan; Kunming Qi; Hai Cheng; Haiying Sun; Feng Zhu; Wei Sang; Depeng Li; Zhenyu Li; Junnian Zheng; Mingfeng Zhao; Aibin Liang; He Huang; Kailin Xu
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

Review 4.  Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.

Authors:  Tong Chen; Yuanbo Liu; Yang Wang; Qing Chang; Jinsong Wu; Zhiliang Wang; Daoying Geng; Jin-Tai Yu; Yuan Li; Xiao-Qiu Li; Hong Chen; Dongxiao Zhuang; Jianyong Li; Bin Wang; Tao Jiang; Lanting Lyu; Yuqin Song; Xiaoguang Qiu; Wenbin Li; Song Lin; Xinghu Zhang; Dehong Lu; Junqiang Lei; Yaolong Chen; Ying Mao
Journal:  J Hematol Oncol       Date:  2022-09-29       Impact factor: 23.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.